
This webinar explores the benefits and limitations of different quantitative analytical techniques for messenger RNA (mRNA) pharmacokinetics/pharmacodynamics and bioanalysis research.
Following the entry of the first messenger RNA (mRNA)-based vaccines into the market with an emergency-use authorization a few years ago, numerous additional mRNA medications with indications beyond preventive care are currently in preclinical and clinical research.
Their exceptional potential won them ‘Breakthrough Therapy’ and ‘Fast Track’ designations from authorities.
Because cellular machinery converts mRNA into proteins, a variety of quantitative assessment methods can be used to aid drug development.
This presentation will cover the advantages and disadvantages of various quantitative analytical methods for mRNA pharmacokinetics/pharmacodynamics and bioanalysis.
It will provide method-development workflows for protein expression analysis, such as sample preparation, surrogate peptide selection, and assessment using liquid chromatography and high-resolution mass spectrometry.
The technique’s easy transfer from high-resolution mass spectrometry to triple quadrupole technology will be examined, as well as verification and validation criteria for controlled bioanalysis in accordance with good laboratory practice.
What will you learn?
- Understand current quantitative methods for mRNA expression analysis
- Explore technique development, including sample preparation, MS setup, and transfer
- Evaluate a case study to verify and validate the method
Who may be interested in this?
- Lab directors and managers
- Senior scientists
- Staff scientists
- Group leaders
- Lab managers
- Principal investigators
- Scientists
- Lab technicians
Speaker:
Aliri Bioanalysis (CO, USA) 
Aliri is a bioanalytical partner that enables bioparma teams to predict the safety and efficacy of their therapy at every stage of development with two distinct and complimentary services: regulatory ready LC-MS based bioanalysis and predictive spatial biology insights.
With over 30 years of experience supporting discovery, preclinical, and clinical studies for both small and large molecules, we maintain rigorous scientific control so our sponsor’s data remains defensible and decision-ready as studies grow.
Our scientists are long-tenured industry veterans that are passionate about giving individual attention to every project and are continuously innovating to stay in lock-step with our sponsors as they bring next-gen molecules to market.